Pharmaceutical | Page 32 of 46

Urinary Tract Infection :: Treatments for urinary infections leave bacteria bald, happy and vulnerable

A different approach to treating urinary tract infections (UTIs) could defeat the bacteria that cause the infections without directly killing them, a strategy that could help slow the growth of antibiotic-resistant infections. Researchers at Washington University School of Medicine in St. Louis have been working to create pharmaceuticals that essentially “defang” the bacteria by preventing them from assembling pili, microscopic hairs that enable the bacteria to invade host cells.

Osteoporosis :: PBS extension to benefit osteoporosis patients

The Australian Government has expanded eligibility for the osteoporosis medication alendronate under the Pharmaceutical Benefits Scheme (PBS).

Schizophrenia :: Eli Lilly’s response about Zyprexa for schizophrenia and bipolar disorder

Eli Lilly and Company (NYSE: LLY), vigorously objects to the characterization of company practices in a New York Times article based upon selective documents illegally leaked by plaintiffs’ lawyers.

CMS re-charters committee to advise on evaluating medical technologies

The Centers for Medicare & Medicaid Services (CMS) today announced that the Medicare Coverage Advisory Committee has been re-chartered through 2008, and as part of this re-charter, the agency has updated the Committee?s role in the Medicare national coverage process.

Botulinum :: Seeing a neurotoxin’s deadly grip

Two Howard Hughes Medical Institute (HHMI) research teams working independently have discovered new information about how the botulinum neurotoxin shuts down neurons with deadly efficiency. By providing detailed views of the toxin plugged into its neuronal receptor, the new studies could aid efforts to engineer specialized versions of the powerful neurotoxin that is used to treat a wide array of medical problems.

Hepatitis :: Abbott, Enanta to Develop and Commercialize HCV Protease Inhibitors

Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide agreement to develop and commercialize hepatitis C virus (HCV) NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated attractive efficacy and pharmacokinetic profiles in pre-clinical studies.

Healthcare :: Licensing Opportunities for Rare Disease Technologies

The National Institutes of Health (NIH) launched a new website today offering technologies available for commercial licensing that are related to rare diseases or conditions. The listing can be found at http://www.ott.nih.gov/rarediseases and currently consists of more than 500 such technologies, including drugs, biologics, and devices, available to be transferred from the NIH and the U.S. Food and Drug Administration (FDA) to the private sector for further research and development and potential commercialization.

Schizophrenia :: ABILIFY, Aripiprazole for Adults With Agitation Associated With Schizophrenia or Bipolar Mania

Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY? (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours).

Egyptian Health Minister Opens AstraZeneca’s New $32M Manufacturing Plant near Cairo

Egyptian Health Minister Dr. Hatem Mostafa El-Gabaly today opened a new $32 million tablet factory built by AstraZeneca near Cairo ? the company?s first manufacturing investment in the Middle East. David Brennan, Chief Executive Officer of AstraZeneca, also attended the opening ceremony at the factory in 6th of October City.

Malaria :: Stop marketing unapproved drug products containing quinine – FDA

The Food and Drug Administration (FDA) today ordered firms to stop marketing unapproved drug products containing quinine, a drug used to treat malaria, citing serious safety concerns, including deaths, associated with quinine products. There are multiple unapproved products containing quinine currently marketed. However, there is only one quinine product approved by the FDA.